JP2010526547A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526547A5 JP2010526547A5 JP2010507858A JP2010507858A JP2010526547A5 JP 2010526547 A5 JP2010526547 A5 JP 2010526547A5 JP 2010507858 A JP2010507858 A JP 2010507858A JP 2010507858 A JP2010507858 A JP 2010507858A JP 2010526547 A5 JP2010526547 A5 JP 2010526547A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- hpv
- acid molecule
- vector
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 41
- 108020004707 nucleic acids Proteins 0.000 claims 40
- 102000039446 nucleic acids Human genes 0.000 claims 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 229920001184 polypeptide Polymers 0.000 claims 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 239000002773 nucleotide Substances 0.000 claims 12
- 125000003729 nucleotide group Chemical group 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108700010070 Codon Usage Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 241001631646 Papillomaviridae Species 0.000 claims 3
- 108700038832 HPV-33 E2 Proteins 0.000 claims 2
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 2
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 claims 2
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims 2
- 101000622322 Human papillomavirus type 16 Regulatory protein E2 Proteins 0.000 claims 2
- 101000954519 Human papillomavirus type 18 Protein E6 Proteins 0.000 claims 2
- 101000767629 Human papillomavirus type 18 Protein E7 Proteins 0.000 claims 2
- 101000622327 Human papillomavirus type 18 Regulatory protein E2 Proteins 0.000 claims 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 229940124669 imidazoquinoline Drugs 0.000 claims 1
- -1 imidazoquinoline compound Chemical class 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07360019.9 | 2007-05-15 | ||
| EP07360019 | 2007-05-15 | ||
| PCT/EP2008/051031 WO2008138648A1 (en) | 2007-05-15 | 2008-01-29 | Vectors for multiple gene expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526547A JP2010526547A (ja) | 2010-08-05 |
| JP2010526547A5 true JP2010526547A5 (https=) | 2011-03-17 |
| JP5474767B2 JP5474767B2 (ja) | 2014-04-16 |
Family
ID=39522406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507858A Expired - Fee Related JP5474767B2 (ja) | 2007-05-15 | 2008-01-29 | 多重遺伝子発現のためのベクター |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8337859B2 (https=) |
| EP (1) | EP2162544B1 (https=) |
| JP (1) | JP5474767B2 (https=) |
| KR (1) | KR101514473B1 (https=) |
| CN (1) | CN101688223B (https=) |
| AR (1) | AR065075A1 (https=) |
| AU (1) | AU2008250520B2 (https=) |
| BR (1) | BRPI0810305A2 (https=) |
| CA (1) | CA2686772C (https=) |
| ES (1) | ES2416361T3 (https=) |
| IL (1) | IL201963A (https=) |
| MX (1) | MX2009012272A (https=) |
| PE (1) | PE20090483A1 (https=) |
| RU (1) | RU2462513C2 (https=) |
| TW (1) | TW200844231A (https=) |
| WO (1) | WO2008138648A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8415462B2 (en) | 2007-05-15 | 2013-04-09 | Transgene S.A. | Signaling peptides |
| WO2010085660A2 (en) * | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| TWI555531B (zh) * | 2009-08-07 | 2016-11-01 | 傳斯堅公司 | 用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物 |
| WO2011127924A2 (de) * | 2010-04-16 | 2011-10-20 | Charité - Universitätsmedizin Berlin | Mittel zur lokalen behandlung von zervixdysplasien |
| GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
| US9216213B2 (en) * | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| ES2646590T3 (es) * | 2012-01-24 | 2017-12-14 | Sanford Health | Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos |
| CA2901501C (en) | 2013-02-21 | 2023-03-07 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Vaccine composition |
| SG10201903349YA (en) * | 2014-10-14 | 2019-05-30 | Univ Pennsylvania | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
| JP2019505512A (ja) | 2016-01-08 | 2019-02-28 | バッシボディ アクスイェ セルスカプ | 治療用抗癌ネオエピトープワクチン |
| EP3452087A1 (en) * | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| EP3518966A1 (en) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| EP3461497A1 (en) * | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| CA3120715A1 (en) * | 2018-11-21 | 2020-05-28 | Mayo Foundation For Medical Education And Research | Adenoviruses and methods for using adenoviruses |
| KR20240086779A (ko) * | 2022-12-05 | 2024-06-19 | 경상국립대학교산학협력단 | 다중 단백질의 발현을 위한 신규 핵산 구조체 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| DE69828284T2 (de) | 1997-06-30 | 2005-12-08 | Nippon Kayaku K.K. | Naphthyridinderivate oder salze davon |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2774699B1 (fr) | 1997-11-17 | 2003-10-03 | Rhone Poulenc Rorer Sa | Methode de reduction des evenements de recombinaison homologue |
| US7001995B1 (en) * | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
| AU772611B2 (en) * | 1999-08-25 | 2004-05-06 | Merck Sharp & Dohme Corp. | Synthetic human papillomavirus genes |
| US20050118139A1 (en) | 2001-08-23 | 2005-06-02 | Lingyi Huang | Vaccine using papilloma virus e proteins delivered by viral vector |
| CN102703393A (zh) * | 2002-05-16 | 2012-10-03 | 巴法里安诺迪克有限公司 | 表达插入痘病毒基因组中的同源基因的重组痘病毒 |
| WO2008092854A2 (en) * | 2007-01-30 | 2008-08-07 | Transgene S.A. | Papillomavirus e2 polypeptide used for vaccination |
-
2008
- 2008-01-29 JP JP2010507858A patent/JP5474767B2/ja not_active Expired - Fee Related
- 2008-01-29 CN CN200880016061XA patent/CN101688223B/zh not_active Expired - Fee Related
- 2008-01-29 CA CA2686772A patent/CA2686772C/en not_active Expired - Fee Related
- 2008-01-29 TW TW097103228A patent/TW200844231A/zh unknown
- 2008-01-29 US US12/599,971 patent/US8337859B2/en not_active Expired - Fee Related
- 2008-01-29 ES ES08708348T patent/ES2416361T3/es active Active
- 2008-01-29 WO PCT/EP2008/051031 patent/WO2008138648A1/en not_active Ceased
- 2008-01-29 RU RU2009144898/10A patent/RU2462513C2/ru active
- 2008-01-29 AR ARP080100356A patent/AR065075A1/es not_active Application Discontinuation
- 2008-01-29 MX MX2009012272A patent/MX2009012272A/es active IP Right Grant
- 2008-01-29 PE PE2008000210A patent/PE20090483A1/es not_active Application Discontinuation
- 2008-01-29 BR BRPI0810305A patent/BRPI0810305A2/pt not_active Application Discontinuation
- 2008-01-29 KR KR1020097023308A patent/KR101514473B1/ko not_active Expired - Fee Related
- 2008-01-29 EP EP08708348.1A patent/EP2162544B1/en not_active Not-in-force
- 2008-01-29 AU AU2008250520A patent/AU2008250520B2/en not_active Ceased
-
2009
- 2009-11-05 IL IL201963A patent/IL201963A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526547A5 (https=) | ||
| RU2009144898A (ru) | Векторы для множественной генной экспрессии | |
| JP2010516287A5 (https=) | ||
| IL215599A (en) | A nucleic acid-encoding vector for proteins 1e and 2e of the papilloma virus | |
| JP2009534331A5 (https=) | ||
| JP2009534332A5 (https=) | ||
| RU2008145712A (ru) | Вакцина против папилломовирусной инфекции на основе вируса папиломы человека впч-16 | |
| US8147839B2 (en) | Fusion proteins of HIV regulatory/accessory proteins | |
| EP3463444B1 (en) | Improvement of hpv l2 peptide immunogenicity | |
| US20100055069A1 (en) | Hpv-18-based papillomavirus vaccines | |
| NZ502632A (en) | Vaccine for use in the treatment or prophylaxis of human papilloma induced tumours | |
| CA2323573A1 (en) | Medicament for preventing or treating papilloma virus-specific tumors | |
| WO2007121893A1 (en) | Method for treating hpv infected patients | |
| HK40006519B (en) | Improvement of hpv l2 peptide immunogenicity | |
| HK40006519A (en) | Improvement of hpv l2 peptide immunogenicity |